A Phase I Dose-Escalation Trial Of Alpha-Tocopheryloxyacetic Acid And Concurrent Trastuzumab In Patients With Treatment Refractory Her2+Metastatic Breast Cancer.

William R Gwin,Jennifer Childs,Doreen Higgins, Kellie Ann Burton, Kristin Kuano,Lauren Corulli,James Dai,Emmanuel T Akporiaye,Mary L. Disis

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览23

暂无评分

摘要

TPS1103Background: Metastatic HER2+ breast cancer, while initially responsive to trastuzumab, pertuzumab, and TDM-1, eventually progresses. The FDA recently approved trastuzumab deruxtecan, showing...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要